Drug Type Interferons, Biosimilar |
Synonyms RHUIFNA-2B, 安达芬 |
Target |
Action agonists, stimulants, inducers |
Mechanism IFNAR agonists(Interferon alpha/beta receptor agonists), Immunostimulants, Innate antiviral immune response inducers |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date China (01 Jan 1997), |
Regulation- |

| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Condylomata Acuminata | China | 01 Jan 1997 | |
| Hairy Cell Leukemia | China | 01 Jan 1997 | |
| Hepatitis B | China | 01 Jan 1997 | |
| Hepatitis C | China | 01 Jan 1997 | |
| Herpes Simplex | China | 01 Jan 1997 | |
| Herpes Zoster | China | 01 Jan 1997 | |
| Herpes Zoster Ophthalmicus | China | 01 Jan 1997 | |
| Human Papillomavirus Infection | China | 01 Jan 1997 | |
| Philadelphia chromosome positive chronic myelogenous leukemia | China | 01 Jan 1997 | |
| Uterine Cervical Erosion | China | 01 Jan 1997 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Herpangina | Phase 2 | China | 25 May 2024 |






